title: Conjugated linoleic acid supplementation in humans--metabolic effects.
abstract: Supplementation with conjugated linoleic acid (CLA) induces a number of physiological effects in experimental animals, including reduced body fat content, decreased aortic lipid deposition, and improved serum lipid profile. Controlled trials on the effects of CLA in humans have hitherto been scarce. The aim of this study was to evaluate the effects of supplementation with CLA in healthy humans on anthropometric and metabolic variables and on the fatty acid composition of serum lipids and thrombocytes. Fifty-three healthy men and women, aged 23-63 yr, were randomly assigned to supplementation with CLA (4.2 g/d) or the same amount of olive oil during 12 wk in a double-blind fashion. The proportion of body fat decreased (-3.8%, P< 0.001) in the CLA-treated group, with a significant difference from the control group (P = 0.050). Body weight, body mass index, and sagittal abdominal diameter were unchanged. There were no major differences between the groups in serum lipoproteins, nonesterified fatty acids, plasma insulin, blood glucose, or plasminogen activator inhibitor 1 (PAI-1). In the CLA group the proportions of stearic, docosatetraenoic, and docosapentaenoic acids increased in serum lipids and thrombocytes, while proportions of palmitic, oleic, and dihomo-gamma-linolenic acids decreased, causing a decrease of the estimated delta-6 and delta-9 and an increase in the delta-5 desaturase activities. These results suggest that supplementation with CLA may reduce the proportion of body fat in humans and that CLA affects fatty acid metabolism. No effects on body weight, serum lipids, glucose metabolism, or PAI-1 were seen.
authors.affiliation: Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Sweden. annika.smedman@pubcare.uu.se
authors.forename: A
authors.initials: A
authors.lastname: Smedman
authors.forename: B
authors.initials: B
authors.lastname: Vessby
mesh_terms: D000328:Adult; D000886:Anthropometry; D001053:Apolipoproteins / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D019587:Dietary Supplements; D004311:Double-Blind Method; D005227:Fatty Acids / Q000032:analysis; D005260:Female; D006801:Humans; D019787:Linoleic Acid / Q000494:pharmacology*; D050356:Lipid Metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008055:Lipids / Q000032:analysis; D008297:Male; D008875:Middle Aged
chemical_list: D001053:Apolipoproteins; D001786:Blood Glucose; D005227:Fatty Acids; D008055:Lipids; D019787:Linoleic Acid